IBRXImmunityBio, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- $113M
- 668% YoY
- Operating margin
- -226.0%
- 90% YoY
- EBITDA
- −$241M
- 26% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired32% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $934K | $240K | $622K | $15M | $113M | 668% |
| Operating income | −$330M | −$351M | −$362M | −$344M | −$256M | 26% |
| Net income | −$350M | −$417M | −$584M | −$414M | −$352M | 15% |
| Operating cash flow | −$274M | −$338M | −$367M | −$391M | −$305M | 22% |
| Capex | $34M | $78M | $31M | $7M | $4M | 44% |
| Stock-based comp | $57M | $40M | $49M | $34M | $37M | 6.9% |
| Buybacks | $0 | — | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $1M · 3
- Net
- −$1M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $13M | $6M | 15 | 120 |
| FY2024 | $11M | $4M | 19 | 91 |
| FY2023 | $1M | $262K | 38 | 92 |
| FY2022 | $4M | $3M | 38 | 89 |
| FY2021 | $29M | $10M | 46 | 99 |